What is the recommended dose of Clomid (clomiphene citrate) for inducing ovulation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dose of Clomid for Ovulation Induction

The recommended initial dose of Clomid (clomiphene citrate) for ovulation induction is 50 mg daily for 5 days, starting on day 5 of the menstrual cycle, with dose increases to 100 mg daily for 5 days if ovulation does not occur after the first course. 1

Dosing Protocol

Initial Treatment

  • Start with 50 mg daily (1 tablet) for 5 days
  • Begin treatment on or about day 5 of the menstrual cycle if spontaneous or progestin-induced bleeding has occurred
  • If no recent uterine bleeding, treatment can be started at any time

Follow-up Treatment

  • If ovulation occurs with the 50 mg dose, maintain this dosage for subsequent cycles
  • If ovulation does not occur after the first course, increase to 100 mg daily (two 50 mg tablets as a single dose) for 5 days
  • Second course can be started as early as 30 days after the previous one (after excluding pregnancy)
  • Do not exceed 100 mg/day or extend treatment beyond 5 days per cycle

Treatment Duration Limitations

  • If ovulation does not occur after three courses of therapy, discontinue clomiphene citrate and reevaluate the patient
  • If three ovulatory responses occur without pregnancy, further treatment is not recommended
  • Long-term cyclic therapy should not exceed approximately six cycles 1, 2

Special Considerations

Patient Selection

  • Lower doses are particularly recommended for patients with suspected sensitivity to pituitary gonadotropins, such as those with polycystic ovary syndrome (PCOS) 1
  • Women with functional hypothalamic amenorrhea (FHA) should achieve a BMI ≥18.5 kg/m² before ovulation induction 3

Monitoring

  • Monitor at least the first cycle with ultrasonography to assess follicular development and minimize risk of multiple pregnancy 4
  • Ovulation typically occurs 5-10 days after completing a course of clomiphene citrate 1
  • Appropriate tests to determine ovulation may be useful during this time

Efficacy and Response

  • The majority of patients who will respond to clomiphene will do so after the first course of therapy 1
  • Approximately 70% of treated patients will ovulate with doses up to 200 mg/day 5
  • Cumulative conception rates approach normal population rates by treatment cycle 12 2

Potential Adverse Effects

  • Multiple pregnancies (increased risk with multiple follicular development)
  • Ovarian hyperstimulation syndrome
  • Effects on cervical mucus and endometrial function may impair fertility in some women 5

Special Situations

Clomiphene Resistance

  • For clomiphene-resistant patients, consider factors such as obesity, hyperandrogenemia, and insulin resistance 4
  • Alternative approaches for clomiphene-resistant patients include gonadotropin therapy or laparoscopic ovarian drilling 4

Low-Dose Protocol

  • In highly sensitive patients who develop functional ovarian cysts at standard doses, doses as low as 12.5 mg daily for 5 days have been effective 6
  • Using 50 mg doses may minimize side effects while maintaining similar efficacy to higher doses 5

Important Caution

Do not increase the dosage or duration of therapy beyond 100 mg/day for 5 days, as this does not improve outcomes and may increase risks 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clomiphene citrate in the twenty-first century.

Human fertility (Cambridge, England), 2001

Research

Clomiphene citrate and ovulation induction.

Reproductive biomedicine online, 2002

Research

Ovulation induction with low doses of clomiphene citrate.

Obstetrics and gynecology, 1986

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.